Purpose: Circulating cell-free DNA (CFDNA) was investigated as potential screening or prognostic markers in a variety of cancers. This study investigated its clinical significance in a homogeneous group of lung cancer patients.
Introduction
Tumors can release genomic DNA into the bloodstream and circulating DNA in the blood can reflect the characteristics of the tumor DNA (1) (2) (3) . Several explanations of the mechanism of cellular DNA release into the circulation have been proposed, including a leakage after tumor necrosis or apoptosis, a lysis of circulating tumor cells or micrometastases, or an active release by tumor cells (3) (4) (5) (6) . Thus, circulating plasma cell-free DNA (CFDNA) may, in theory, represent tumor burden or tumor biologic aggressiveness, regardless of the releasing mechanisms. A series of studies has shown that lung cancer patients have higher levels of CFDNA in the blood compared with healthy controls (7) (8) (9) . However, the prognostic or predictive value of circulating plasma CFDNA for the treatment outcomes and survival of lung cancer patients remains controversial (9) (10) (11) (12) (13) (14) (15) . Several studies have reported that a higher CFDNA concentration was associated with poorer survival in lung cancer patients (10) (11) (12) . However, other studies failed to show its correlation with overall survival (OS) in lung cancer groups (13) (14) (15) . This discrepancy may be explained, in part, by the followings facts. First, the majority of previous studies were based on retrospective data which was collected with inevitable selection bias. Second, the numbers of subjects were not sufficient to show a survival difference. Third, there was some inconsistency in the method of measuring the CFDNA concentrations. Finally, the heterogeneity of the subjects in terms of their tumor types, stages, and treatments might have affected the survival outcomes.
In this study, we investigated the clinical significance of plasma CFDNA in a homogeneous group of lung cancer patients. The subjects of this study were never smokers with advanced lung adenocarcinoma, who were enrolled in a prospective randomized phase III study that compared gefitinib with gemcitabine plus cisplatin (GP) as the first-line treatment. Real-time quantitative PCR (qPCR), the current standard method of quantifying DNA, was used in this study. We investigated whether CFDNA in the plasma reflects tumor burden or aggressiveness and whether it can predict the treatment outcomes and survival in this population.
Materials and Methods

Patients and sample collection
The First-SIGNAL study was a phase III, multicenter, randomized, open-label, parallel-group study that compared gefitinib with GP as the first-line treatment for never smokers with advanced or metastatic adenocarcinoma of the lung (ClinicalTrials.gov number, NCT00455936; ref. 16) . Among a total of 309 patients, an optional blood sample for a collateral study was taken from 134 patients at the National Cancer Center Hospital (Goyang, Republic of Korea) after the patients had given their written informed consent, with the approval of the Institutional Review Board (Supplementary Fig. S1 ). In the gefitinib arm, gefitinib was administered at a daily dose of 250 mg until progression, whereas in the chemotherapy arm, gemcitabine 1,250 mg/m 2 (days 1 and 8) and cisplatin 80 mg/m 2 (day 1) were given every 3 weeks for up to 9 cycles. The tumor response was assessed every 3 cycles with computed tomography (CT). The collection of blood sample was planned to occur at baseline and every 3 cycles of the first-line treatment.
Quantification of circulating plasma CFDNA Blood samples were collected in EDTA-coated tubes and centrifuged immediately at 1,000 Â g for 15 minutes. The plasma was carefully separated and stored at À80 C. The DNA was extracted from 200 mL of plasma by using the QIAamp DNA Blood Mini Kit (Qiagen), according to the manufacturer's instructions. The DNA was eluted in a final volume of 50 mL. To measure the plasma CFDNA concentration, the genomic sequence encoding b-actin (ACTB) was amplified by real-time qPCR. The primers and fluorescent probe used for the qPCR assay were as described by Herrera and colleagues (17) . The purified plasma DNA (2 mL) was amplified using 0.3 mmol/L of each primer (5 0 -CCACACTGTGCCCATCTACG-3 0 and 5 0 -AGGATCTTCAT-GAGGTAG TCAGTCAG-3 0 ) and 0.25 mmol/L of fluorescent probe (5 0 -FAM-ATGCCCTCCCCCATGCCATCCTGCGT-TAMRA-3 0 ). The PCR was done with the following program: 10 minutes at 95 C, followed by 40 cycles of 15 seconds at 95 C and 1 minute at 60 C. Quantitative standard curves were prepared by using serially diluted control genomic human DNA (Applied Biosystems). The fluorescence of the amplified PCR products was detected with an ABI 7900HT Sequence Detection System (Applied Biosystems). The results of the qPCR assay represent the means of 3 independent experiments, each consisting of duplicate samples.
EGFR mutation analysis in tumor DNA
We analyzed mutations of the epidermal growth factor receptor (EGFR) gene on tumor biopsy samples retrieved from 47 patients. Nucleotide sequencing of the kinase domain of EGFR gene (exons 19 and 21) was done by using nested PCR amplification of the individual exons. The details of the sequencing procedure are described elsewhere (18) . A deletion mutation in exon 19 and a point mutation (CTG > CGG) in exon 21 (L858R) were considered sensitive EGFR mutations.
Assessment
Progression-free survival (PFS) was measured from the first day of first-line therapy until the first documentation of disease progression or death. OS was calculated from the first day of first-line therapy until death or the most recent follow-up. Tumor response was assessed in accordance with the guidelines established by the standard World Health Organization criteria (19) . The size of the primary tumor was determined as the largest diameter of the primary tumor on a CT image. The numbers of organ sites with distant metastases were also counted on CT images, brain MRIs, and whole-body bone scans.
Statistical analysis
The distributions of plasma CFDNA concentrations were extremely right skewed (skewness of the baseline plasma CFDNA ¼ 3.47). Therefore, the plasma CFDNA concentrations were log transformed (natural logarithms) for all statistical analyses (Supplementary Fig. S2 ). Correlations between plasma CFDNA and categorical or continuous
Translational Relevance
A large number of molecular and biologic features have been investigated for an early detection and prognostic prediction of non-small cell lung cancer. Most of these biomarkers are based on analysis using tumor tissue samples and thus have a limitation in respect of technical feasibility. Circulating cell-free DNA (CFDNA) in the plasma has been expected as a good candidate of prognostic marker in several kinds of cancers because of greater accessibility. However, in lung cancer patients, the prognostic or predictive value of CFDNA remains controversial. The current study investigated its clinical significance in a homogeneous group of advanced lung adenocarcinoma patients who were enrolled in a prospective randomized phase III study. Consequently, this study showed that high plasma CFDNA before treatment is associated with aggressive tumor behavior and poor survival outcomes in these patients. In addition, plasma CFDNA might facilitate the selection of groups of patients who would benefit from specific types of therapy.
variables were tested with a t test, 1-way ANOVA, or Pearson's correlation coefficient, where appropriate. The differences in radiological tumor responses between the groups were tested with the c 2 test. The change in plasma CFDNA between before and after treatment was assessed with the Wilcoxon matched-pairs signed-rank test. Survival time was estimated by using the Kaplan-Meier method, and survival difference between each group was assessed with 
Results
Patient characteristics
The median age was 56 years (range, 24-76 years). Twenty-six patients (19.4%) had recurrent tumor after surgical resection before first-line chemotherapy. Half the patients (n ¼ 67) received gefitinib and the other half received GP chemotherapy as the first-line treatment. The median follow-up time was 36.0 months (95% CI, 33.6-37.9 months). The median PFS and OS for the entire group were 6.35 months (95% CI, 5.2-7.2 months) and 23.3 months (95% CI, 17.8-28.7 months), respectively. Among the 132 evaluable patients, 66 (50.0%) showed a tumor response to the first-line therapy: 52.2% (35/67) in the gefitinib arm and 47.7% (31/65) in the chemotherapy arm.
Plasma CFDNA
Among 134 patients whose baseline plasma CFDNA was measured, 108 patients (80.6%) completed the planned blood sampling. Plasma CFDNA at progressive disease (PD) after first-line therapy was measured in only 108 (83.1%) of the 130 patients with confirmed PD. Among 97 patients showing partial response (PR) and stable disease (SD), plasma CFDNA was measured at the time of the best response in 91 patients (93.8%), when the smallest sum of target tumor lesions was documented on a radiological examination. The median sampling interval between baseline and the best response was 17.9 weeks (95% CI, 15.2-18.8 weeks) and the median sampling interval between the best response and disease progression was 15.0 weeks (95% CI, 13.2-28.2 weeks). Baseline plasma CFDNA ranged from 11.5 to 2,487.9 ng/ mL, with a median value of 122.3 ng/mL and a mean value of 263.0 ng/mL. The median values for CFDNA at the best response (n ¼ 91) and at disease progression (n ¼ 108) were 116.7 ng/mL (range, 24.1-8274 ng/mL) and 157.0 ng/mL (range, 19.8-1,298.4 ng/mL), respectively. For the outcome analysis, patients were divided into 3 subgroups according to the tertiles of log-transformed baseline plasma CFDNA. The tertile cutoff values were 4.34 and 5.26.
Plasma CFDNA and clinicopathologic characteristics
The baseline plasma CFDNA concentration had no association with age, sex, performance status, stage, T-stage, metastatic sites, or EGFR mutational status ( Table 1) significantly with baseline plasma CFDNA, whereas the size of the primary tumor did not. Patients with more than 2 metastatic sites had higher plasma CFDNA at baseline than patients with 2 or fewer metastatic sites (P ¼ 0.015). The level of plasma CFDNA was higher in tumors with advanced locoregional lymph nodes (P ¼ 0.033). The size of the primary tumor, which was measurable on CT images in 131 patients [with a median value of 37 mm (range, 14.0-94.7 mm)], showed no statistically significant correlation with plasma CFDNA (coefficient ¼ À0.004; P ¼ 0.961; Supplementary Fig. S3 ).
Changes in plasma CFDNA after treatment
The changes in CFDNA levels after first-line therapy according to the tumor response in each baseline CFDNA group were as follows. In the low tertile CFDNA group, CFDNA increased after treatment, regardless of the tumor response status. In this group, the median percentage change in CFDNA was 18.9% (P ¼ 0.001) in the PR subgroup, 10.9% (P ¼ 0.010) in the SD subgroup and 20.5% (P ¼ 0.008) in the early failure group (PD). In the middle tertile CFDNA group, there was no significant difference in the median percentage change in CFDNA according to the tumor response status [5.5% (P ¼ 0.330) in PR, 3.3% (P ¼ 0.214) in SD, and 4.9% (P ¼ 0.069) in PD]. In patients with high tertile baseline CFDNA, CFDNA tended to decrease after treatment and the median percentage changes in CFDNA in PR, SD, and PD were À18.6% (P ¼ 0.005), À9.5% (P ¼ 0.686), and À18.5% (P ¼ 0.046), respectively. These patterns of change in CFDNA in each baseline CFDNA group after first-line therapy did not differ according to the treatment arm, as shown in Figure 1 .
Plasma CFDNA and tumor response
Two patients were lost to follow-up without evaluation of their responses and thus, the responses of 132 patients were evaluated. Median baseline CFDNA values of 3 response groups (PR, SD, and PD) were 3.84, 4.89, and 5.07, respectively in the GP arm (P ¼ 0.008) and 4.77, 4.74, and 5.21, respectively in the gefitinib arm (P ¼ 0.732; Fig. 2A ). Overall, there was no significant difference in the response rate among the 3 tertile groups of baseline CFDNA (response rates: 40.9%, 54.8%, and 54.3% in the low, middle, and high tertile CFDNA group, respectively; P ¼ 0.336), although the low tertile group showed a lower response rate after GP treatment than the other groups (26.1%, 57.9%, and 60.9%, respectively; P ¼ 0.035; Fig. 2B ). However, in the subgroup of patients who were treated with gefitinib first, there was no difference in the response rates of the 3 CFDNA groups (57.1%, 47.4%, and 51.9%, respectively; P ¼ 0.825). Thus, using the cut point to divide the low tertile group and the other groups, the following performance indices for response prediction were obtained: a sensitivity of 81% versus 66%, a specificity of 50% versus 28%, a positive predictive value of 60% versus 50%, and a negative predictive value of 74% versus 43% in the GP versus gefitinib treatment arm, respectively.
Plasma CFDNA and survival outcomes
The analysis of PFS revealed that the treatment regimen was the only significant predictor of PFS. The risk of progression was higher in the chemotherapy arm than in the gefitinib arm [HR for chemotherapy vs. gefitinib ¼ 1.46 (95% CI, 1.001-2.14); median PFS, 6.4 vs. 5.7 months, respectively; P ¼ 0.049]. However, baseline plasma CFDNA did not predict PFS [HR of high vs. low CFDNA ¼ 1.48 (95% CI, 0.96-2.29); median PFS, 5.3 vs. 6.6 months, respectively; P ¼ 0.301; Fig. 3A] .
However, the univariate analysis of OS showed that age, Eastern Cooperative Oncology Group (ECOG) performance status, and baseline plasma CFDNA were significant predictors of survival (Table 2 ). In the multivariate analysis, ECOG performance status and baseline plasma CFDNA remained independent predictors of survival. The high tertile CFDNA group showed a significantly shorter survival than the low tertile CFDNA group [HR of high vs. low CFDNA ¼ 2.70 (95% CI, 1.16-4.91); median OS, 16.0 vs. 28.6 months, respectively; P ¼ 0.041; Fig. 3B ]. Moreover, a similar association between baseline plasma CFDNA and OS was observed when baseline plasma CFDNA was analyzed as a continuous variable. The risk of death was higher with higher baseline plasma CFDNA (HR ¼ 1.23; 95% CI, 1.01-1.50; P ¼ 0.045).
Timing of gefitinib treatment
Among the 67 patients treated with first-line chemotherapy, 51 (76.1%) patients received gefitinib as the second-line therapy, including 18 (75%) with low CFDNA, 20 (83%) with middle CFDNA, and 13 (68%) with high CFDNA. Thus, a total of 118 patients received gefitinib as the first-line or second-line therapy. There was no survival difference according to the timing of gefitinib treatment [HR of second-line vs. first-line gefitinib ¼ 1.22 (95% CI, 0.78-1.92); median OS, 23.0 vs. 26.3 months, respectively; P ¼ 0.382]. When survival was analyzed according to the subgroup of baseline plasma CFDNA, patients in the high tertile CFDNA group treated with second-line gefitinib showed significantly worse survival than patients treated with first-line gefitinib [HR of second-line vs. first-line gefitinib ¼ 2.56 (95% CI, 1.07-6.13); median OS, 16.0 vs. 26.4 months, respectively; P ¼ 0.034), whereas this was not true in the middle and low gefitinib CFDNA groups (Table 3 ). 
Discussion
To the best of our knowledge, this is the first study to evaluate the clinical significance of plasma CFDNA in a homogeneous group of patients prospectively enrolled in a study with a predefined and uniform treatment protocol. Our results suggest that pretreatment levels of plasma CFDNA can be used as a prognostic factor for OS in never smokers with advanced lung adenocarcinoma. This is consistent with the previous study of Gautschi and colleagues, who reported a significant association between increased plasma DNA and poor survival in 163 patients with non-small cell lung cancer (NSCLC) of any histologic type and stage (10) . Two recent studies have also shown the prognostic value of plasma DNA in similar patient populations (11, 12) . However, 3 other studies reported no relationship between plasma DNA and OS (13) (14) (15) .
This study suggests that the predictive value of plasma CFDNA for the tumor response varies with the type of treatment used. Circulating CFDNA in the plasma was not predictive of the response to gefitinib but was predictive of the response to chemotherapy. The predictive factors for drugs that target specific molecular mechanisms, such as gefitinib, seem to be quite different from those for cytotoxic chemotherapy, which is more active against rapidly proliferating tumor cells. Some activating mutations in the tyrosine kinase domain of the EGFR gene are known to be the most important predictive factor for sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs; refs. [20] [21] [22] [23] [24] . In this study, there was no significant association between activating EGFR mutations and circulating plasma CFDNA. This is consistent with the lack of predictive value of plasma CFDNA for gefitinib sensitivity.
The kinetics of CFDNA levels in the plasma did not correlate with the response to treatment. In this study, a significant reduction in plasma CFDNA was observed at the time of tumor response in the high tertile CFDNA group. However, a decreasing trend was also noted during PD in the same group. In contrast, several studies have reported a significant effect of anticancer treatments on CFDNA kinetics (9, 10, 13-15). Gautschi and colleagues showed a significant increase in plasma CFDNA during PD but no reduction in plasma CFDNA in nonPD (10) . In the study by Sozzi and colleagues, plasma CFDNA levels were significantly higher in patients who relapsed after surgery, but reductions were also frequent in this group (9) . This discrepancy might indicate the limitations of the analysis of the overall amount of CFDNA because it does not only detect the changes in tumor-specific CFDNA. Thus, further studies of the origins and kinetics of plasma CFDNA are required to explain this phenomenon.
Recently, to identify EGFR mutation-positive tumors has become a standard procedure for patients with advanced NSCLC, so that EGFR-TKIs can be offered to this specific group as a first-line therapy. This strategy is based on several clinical studies that have shown that first-line EGFR-TKIs afford longer PFS than first-line chemotherapy in patients with lung cancer who are selected based on EGFR mutations (16, (25) (26) (27) . It has also been noted that first-line EGFR-TKIs are superior to first-line chemotherapy in terms of drug tolerability and quality of life. Our data suggest that gefitinib may be much preferred as a first-line treatment in never smokers with lung adenocarcinoma having a high CFDNA level at baseline, which means initially larger tumor burden and more aggressive disease, even though the sample size of subgroup analysis was too small to ensure the statistical significance.
In the GP arm of this study, the high tertile CFDNA group had a higher response rate after first-line chemotherapy but rather showed significantly worse survival compared with the low tertile CFDNA group. This result may be just random effect because tumor response is considered as a surrogate marker for good prognosis. However, this discrepancy also may be a phenomenon which mechanism has not been discovered yet. We can find out several reports similar to this study in the literature. For example, a proliferation marker, such as Ki-67 and mitotic index, predicts better response to neoadjuvant chemotherapy in early breast cancer, although it is associated with worse disease-free survival and OS (28) (29) (30) . In addition, Lee and colleagues reported that tumors with high fludeoxyglucose uptake on pretreatment positron emission tomography exhibit higher response to chemotherapy but shorter time to progression in advanced NSCLC (31) . The authors suggested that tumors with a high standardized uptake values (SUV) respond to chemotherapy initially but then rapidly progress whereas tumors with a low SUV do not show a marked response but progress rather slowly. Thus, if plasma CFDNA can be correlated with tumor proliferation, higher response rate after GP treatment in patients with high CFDNA level can be explained in terms of rapidly proliferating tumor cells and their high sensitivity to cytotoxic chemotherapy. The above markers may help to identify patients who have good response but poor survival outcomes. However, these findings should be further evaluated and validated in future studies.
Plasma CFDNA can originate from normal cells and tumor cells (3) . Therefore, the total amount of CFDNA in the plasma might not be an adequate surrogate marker for tumor DNA compared with tumor-specific CFDNA, which can be detected by the presence of genetic and epigenetic alterations that are specific to the primary tumor. However, tumor-specific CFDNA comprises only a very small fraction of the total circulating CFDNA, limiting its value in clinical practice. Nevertheless, our data indicate that high plasma CFDNA at diagnosis is associated with poor survival outcomes in never smokers with advanced lung adenocarcinoma, which might facilitate the selection of groups of patients who would benefit from specific types of therapy.
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